The problem is that most of the pharmacological evidence is sparse and anecdotal at worst (except for remedisivir, and now lopinavir/ritonavir/ribavirin/interferon beta). Trials are ongoing and should at least give better answers, or hints.
Protocols change among countries or even across hospitals, so it's kind of hard to figure out which treatment is best. There's a lot of road to cover to come to proper treatments, but if we are to believe case reports, it is undoubtedly much better than when the pandemic started hitting the West.
Many countries have already brought their case rates down to almost 0, and every single one that attempted to resume economic activity saw the case rates spike again, with many now re-introducing distancing measures again. This genie is not going back into the bottle.
The first option is actually potentially more viable on a reasonable timeline than vaccination, especially if we manage to find some kind of effective therapeutics which reduce the ICU and mortality rates.
There is however a potential issue, which is based on SARS data, immunity in recovered individuals only lasts 1-2 years. So unless there's a concerted effort to eradicate via immunisation, there's a measurable risk that SARS-CoV-2 will become a seasonal repeating wave like Influenza.
But I'm optimistic, the current situation has everyone focused on the issue. Except Trump trying to get some special deals for early access or whatever the fuck it is that he's doing.
As an example, Moderna teamed up with Lonza (and also got a big grant from BARDA). Oxford / Vaccitech has deals with Astra Zeneca, Merck, and a few other manufacturers.